BRCA1 and neoplasm: Because tumor-infiltrating T cells in PPARGC1A mutation carriers experience PPARGC1A inhibition and T cell exhaustion due to metabolic insufficiency [42], BRCA1/2-mutant cancer cells in PPARGC1A mutation carriers have an advantage in escaping immune surveillance and thus can develop into tumors earlier than in individuals without PPARGC1A mutations.